RxDoctor Payments Data

Courtney Gibson, NP

Family · Hillsboro, ORNPI 1689236077

Payments from drug & device makers

$2,364in general payments, 2019–2025

Across 43 payments — averaging $54.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$727
  • Johnson & Johnson$583
  • E.r. Squibb & Sons, L.L.C.$273
  • GSK$209
  • AstraZeneca$159
  • Sobi, Inc$156
  • plus $256 from 10 others

What the payments were for

  • Consulting fees$66028%
  • Food & beverage$1,48663%
  • Education$2189%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,364 in reported general payments places this provider in the 90th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$20,289
Medicare patients
122
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate19$315,035
EliquisApixaban27$14,804
Abiraterone Acetate12$14,168
Levothyroxine Sodium64$655
Omeprazole17$344
Prednisone71$340
Anastrozole14$249
Prochlorperazine Maleate17$211
Hydroxyurea11$132
Lorazepam14$121
Ondansetron OdtOndansetron12$108
Potassium Chloride15$104
Gabapentin17$51
Escitalopram Oxalate11$40
Furosemide12$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$159$315,03519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,130 family providers in Oregon.

Other family in Hillsboro

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →